Sight Sciences (NASDAQ:SGHT) CEO Paul Badawi Sells 28,684 Shares of Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CEO Paul Badawi sold 28,684 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $5.42, for a total value of $155,467.28. Following the completion of the sale, the chief executive officer owned 6,122,472 shares in the company, valued at $33,183,798.24. The trade was a 0.47% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Sight Sciences Trading Up 0.6%

NASDAQ:SGHT opened at $5.48 on Tuesday. The company has a market cap of $298.17 million, a P/E ratio of -7.72 and a beta of 2.38. Sight Sciences, Inc. has a twelve month low of $3.11 and a twelve month high of $9.24. The business has a 50 day moving average price of $4.95 and a two-hundred day moving average price of $5.31. The company has a quick ratio of 5.48, a current ratio of 5.86 and a debt-to-equity ratio of 0.68.

Sight Sciences (NASDAQ:SGHT) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.05). The business had revenue of $19.70 million during the quarter, compared to analyst estimates of $18.46 million. Sight Sciences had a negative net margin of 46.83% and a negative return on equity of 52.34%. As a group, analysts expect that Sight Sciences, Inc. will post -0.6 EPS for the current fiscal year.

Hedge Funds Weigh In On Sight Sciences

Several large investors have recently modified their holdings of SGHT. Americana Partners LLC grew its stake in Sight Sciences by 12.1% in the 4th quarter. Americana Partners LLC now owns 1,378,980 shares of the company’s stock valued at $10,935,000 after buying an additional 149,161 shares during the last quarter. Palumbo Wealth Management LLC acquired a new position in Sight Sciences in the 4th quarter valued at $294,000. Long Focus Capital Management LLC boosted its position in shares of Sight Sciences by 1.3% in the third quarter. Long Focus Capital Management LLC now owns 3,193,305 shares of the company’s stock valued at $10,985,000 after acquiring an additional 41,797 shares during the period. Dimensional Fund Advisors LP raised its stake in Sight Sciences by 13.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 341,681 shares of the company’s stock worth $1,288,000 after purchasing an additional 40,346 shares in the last quarter. Finally, WealthTrust Asset Management LLC grew its position in shares of Sight Sciences by 14.1% during the 1st quarter. WealthTrust Asset Management LLC now owns 44,635 shares of the company’s stock worth $168,000 after purchasing an additional 5,529 shares in the last quarter. 55.51% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on SGHT shares. Weiss Ratings downgraded shares of Sight Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, May 11th. Citigroup raised their price target on Sight Sciences from $4.35 to $5.15 and gave the company a “neutral” rating in a research note on Thursday, May 28th. Five research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $8.14.

Sight Sciences Company Profile

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.